Infertility
Conditions
Interventions
rFSH :rFSH
rFSH+rLH :rFSH+rLH
Sponsors
West China Second Hospital, Sichuan University
Eligibility
Sex/Gender
Female
Age
20 Years to 35 Years
Inclusion criteria
Inclusion criteria: The study population included patients who were treated in the reproductive medicine center of the second West China Hospital from March 2021 to March 2022 and who were treated with GnRH antagonist for the first time in IVF / ICSI, with basal FSH 4; BMI 18 ~ 28KG / m2. None of these patients had a history of recurrent failure (patients with more than 2 cycles) or recurrent implant failure. Serum LH <= 4IU/L (follicle diameter reached 12mm) was selected as the threshold standard. According to the following criteria, the subjects were randomly divided into two groups: the experimental group added rLH when the diameter of follicle reached 12mm, and the control group only used FSH: 1. In IVF / ICSI subjects treated with GnRHa antagonist of r-hFSH, LH <= 4iu / L; 2. Female subjects between 20 and 35 years old; 3. Subjects whose uterine cavity can maintain embryo implantation or pregnancy; 4. There are no known subjects infected with HIV, hepatitis B or C virus and other infectious diseases unsuitable for pregnancy; 5. Subjects willing to participate and comply with the protocol during the study; 6. Subjects who had obtained informed consent prior to any procedure related to the study and knew that the treatment was not a routine medical service.
Exclusion criteria
Exclusion criteria: 1. Repeated implantation failure (3 or more embryo transfers or more than 4 high-quality embryos in total, all failed to get pregnant); 2. Repeated failure of promoting ovulation (the previous cycle of promoting ovulation was more than 2 times); 3. Endocrine disorders such as PCOS, hypothalamus hypophysis, or ovarian dysfunction such as dor patients; 4. Subjects with clinically significant systemic diseases (e.g., insulin-dependent diabetes, epilepsy, severe migraine, intermittent porphyria, liver, kidney or cardiovascular disease, severe corticosteroid dependent asthma); 5. Any contraindications to pregnancy and / or childbirth; 6. The abnormal source of gynecological bleeding was unknown; 7. Subjects allergic to gonadotropin preparations; 8. Subjects in any medical condition prohibited from using gonadotropin preparations; 9. Subjects who have participated in this study or another clinical drug trial at the same time; 10. Subjects with any active substance abuse or history of drug, drug or alcohol abuse in the past 5 years; 11. Subjects who refused or were unable to comply with the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of oocytes retrieved;number of embryos available; | — |
Secondary
| Measure | Time frame |
|---|---|
| M? oocyte;good quality embryos;clinical pregnancy rate of fresh embryo transfer cycle;ongoing pregnancy rate;clinical pregnancy rate on the first embryo transfer;occurring rate of ovarian hyperstimulation syndrome; | — |
Countries
China
Contacts
Public ContactTian Tang
West China Second Hospital, Sichuan University
Outcome results
None listed